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tions in TP53 and the other genes of interest 
after allogeneic hematopoietic stem-cell trans-
plantation.
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The authors reply: In response to Fozza: we 
found no association between acute GVHD (<100 
days after transplantation) and mutation clear-
ance 30 days after transplantation with the use 
of a variant allele frequency threshold of 0.5% 
(P = 0.64). Approximately 67% (95% confidence 
interval [CI], 52 to 79) of patients with a muta-
tion with a maximum variant allele frequency of 
less than 0.5% at day 30 and approximately 59% 
(95% CI, 41 to 76) of patients with a mutation 
with a maximum variant allele frequency of at 
least 0.5% at day 30 had acute GVHD. Our analy-
sis of chronic GVHD was limited by the availabil-
ity of data for the cohort. A large prospective 
clinical trial incorporating detection of muta-
tions after transplantation with uniform collec-
tion of standardized data on GVHD would be 
ideal to study this question.
In response to Zhu: we were unable to per-
form a stratified analysis because the sample 
sizes in the four groups defined by the presence 
or absence of mutations with a maximum vari-
ant allele frequency of at least 0.5% at day 30 and 
the presence or absence of a TP53 mutation were 
too small to separately estimate the combinato-
rial effects of these two factors. However, several 
statistical models indicate that a mutation with 
a maximum variant allele frequency of at least 
0.5% at day 30 provided a significantly better 
association with disease progression in our study 
than TP53 mutation status. We used the likeli-
hood ratio test to compare two univariate models 
(one with a mutation with a maximum variant 
allele frequency at day 30 and one with TP53 
mutation status as the sole predictors) with a 
bivariate model that included both variables. 
Results of the likelihood ratio test indicated that 
a mutation with a maximum variant allele fre-
quency at day 30 alone provided as much infor-
mation about disease progression as a mutation 
with a maximum variant allele frequency and 
TP53 mutation status together. Although removal 
of TP53 from the bivariate model had no detect-
able effect (P = 0.14), removal of a mutation with 
maximum variant allele frequency resulted in a 
model that fit less well and contained less infor-
mation about progression (P = 0.002). These re-
sults, combined with our multivariable analysis, 
suggest that the persistence of any disease-asso-
ciated mutation provides information about pro-
gression in addition to that provided by TP53 
mutation status.
Meagan A. Jacoby, M.D., Ph.D. 
Kathryn Trinkaus, Ph.D. 
Matthew J. Walter, M.D.
Washington University School of Medicine 
St. Louis, MO 
mjwalter@ wustl . edu
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
DOI: 10.1056/NEJMc1813470
Heat-Stable Carbetocin to Prevent Postpartum Hemorrhage
To the Editor: Widmer et al. (Aug. 23 issue)1 dis-
cuss the use of carbetocin versus oxytocin to pre-
vent hemorrhage after vaginal birth. Carbetocin 
has the potential to be an important uterotonic 
contribution to the compendium of medicines 
administered to prevent postpartum hemorrhage. 
However, carbetocin cannot fully replace oxyto-
cin but should instead be considered part of a 
suite of maternal medicines (including uteroton-
ics and tranexamic acid) used in a collective 
strategy to reduce deaths from postpartum hem-
orrhage, which is still the leading cause of ma-
ternal death. The administration of carbetocin or 
oxytocin during the third stage of labor can pre-
vent postpartum hemorrhage; when these medi-
cines are not available, misoprostol is also effec-
tive. Either oxytocin or misoprostol can be used 
for induction, with misoprostol being the first-
line medicine identified by the World Health Or-
ganization for use in low- and middle-income 
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countries. It is important to note that only oxyto-
cin can be used for labor augmentation; carbeto-
cin and misoprostol cannot be substituted for 
oxytocin for this purpose, in part because of 
their long half-lives. It is essential that clinicians, 
pharmacists, procurers, policymakers, program 
managers, and others be aware of and use this 
information regarding the key roles of these 
medicines to guide their work in counseling clients 
and procuring medicines.
Deborah Armbruster, C.N.M., M.P.H.
U.S. Agency for International Development 
Washington, DC 
darmbruster@ usaid . gov
Thomas Burke, M.D.
Harvard Medical School 
Boston, MA
Andrew Weeks, M.D.
University of Liverpool 
Liverpool, United Kingdom
This letter reflects the views of the authors and does not nec-
essarily reflect the views of the U.S. Agency for International 
Development or the U.S. government.
Dr. Weeks reports being one of the inventors of a device used 
to treat postpartum hemorrhage and serving as scientific advi-
sor to Azanta. No other potential conflict of interest relevant to 
this letter was reported.
1. Widmer M, Piaggio G, Nguyen TMH, et al. Heat-stable carbe-
tocin versus oxytocin to prevent hemorrhage after vaginal birth. 
N Engl J Med 2018; 379: 743-52.
DOI: 10.1056/NEJMc1812692
The authors reply: Our trial showed that heat-
stable carbetocin is noninferior to oxytocin in 
preventing postpartum hemorrhage. Heat-stable 
carbetocin maintains its stability at 40°C for 
6 months and at 30°C for more than 3 years1 and 
is not associated with the concerns about quality 
attached to oxytocin and other uterotonics. It is 
for these reasons that the use of heat-stable car-
betocin in settings without reliable cold-chain 
transport and storage could be of substantial 
benefit to women. We agree with Armbruster 
and colleagues that oxytocin has other indica-
tions for use in relation to childbirth. Policymak-
ers should make efforts to secure adequate cold-
chain transport and storage for oxytocin to ensure 
its quality regardless of the indication. Heat-stable 
carbetocin should be regarded as part of a suite 
of maternal medicines used collectively to reduce 
the risk of death from postpartum hemorrhage.
A. Metin Gülmezoglu, M.D., Ph.D. 
Mariana Widmer, M.Sc.
World Health Organization 
Geneva, Switzerland 
gulmezoglum@ who . int
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
1. Malm M, Madsen I, Kjellström J. Development and stability 
of a heat-stable formulation of carbetocin for the prevention of 
postpartum haemorrhage for use in low and middle-income 
countries. J Pept Sci 2018; 24(6): e3082.
DOI: 10.1056/NEJMc1812692
Case 28-2018: A Man with Epistaxis, Pain and Erythema  
of the Forearm, and Pancytopenia
To the Editor: In the Case Record, Iyasere et al. 
(Sept. 13 issue)1 describe a patient who received a 
diagnosis of hairy-cell leukemia complicated by 
a bacterial infection. Hairy-cell leukemia common-
ly manifests with infection, an important cause 
of illness and potential death in patients with 
this form of cancer. We have some comments 
on the management of this condition. Although 
a 7-day course of cladribine is shorter than a 
course of pentostatin, myelosuppression can be 
profound and prolonged with both purine nucleo-
side analogues; recovery of the immune system 
is not shorter with cladribine than with pento-
statin. In the initial trials of cladribine involving 
patients with hairy-cell leukemia, those with ac-
tive infection were excluded from enrollment.2,3
In contrast to the recovery of the immune 
system associated with purine nucleoside ana-
logues, the median time to neutrophil recovery 
in patients who have received the BRAF inhibitor 
vemurafenib is approximately 4 weeks.4 Although 
vemurafenib is not approved for the treatment of 
hairy-cell leukemia, it has been used off-label in 
selected patients with hairy-cell leukemia and 
active infection as a bridge to neutrophil recov-
ery and control of infection. Eradication of infec-
tion in these patients before the administration 
of myelosuppressive therapy is of prime impor-
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